How 'open' will Big Pharma get to treat R&D ills?

It seems like every month Big Pharma companies roll out a new partnership or initiative to ease their pipeline pains, which include skyrocketing costs of drug development and historically unproductive research. FiercePharma Editor Tracy Staton took a dive into the world of "open" collaboration in the drug business, and how a spate of efforts among drugmakers to join forces on a range of research woes has captivated the industry. The big question is, will these efforts work? Download



Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.